12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

PA32540 regulatory update

Pozen submitted a combined NDA to FDA for PA32540 and its lower dose formulation, PA8140, for the secondary prevention of cardiovascular disease in patients at risk...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >